Welcome to the 13th International Congress on Autoimmunity interactive program

Session Description:

Autoimmune diseases are highly heterogeneous and thus require a more precise approach to medicine. Over several decades, various literature underscored the significance of autoantibodies as biomarkers aiding in the diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course, and stratified therapy of autoimmune disease. Numerous technologies for autoantibody profiling have been developed and growing number of proof sources support the value of combining markers in improving diagnostic accuracy. Multi-analyte technologies, including the new autoantibody system called Aptiva®, show significant benefit for autoantibody profiling. Here we get a glimpse of recent clinical performance and multiparametric modelling data derived from multi-center studies on the Aptiva Connective Tissue Disease (CTD) and Celiac Disease (CD) panels. Additionally, we review the evolution and application of algorithmic analysis in discovering important biomarker signatures and their clinical utilities in autoimmunity.